{"brief_title": "Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis", "brief_summary": "The objective of the study is to evaluate the safety and efficacy of etanercept in comparison with placebo in a double-blind, parallel, randomized fashion in subjects with idiopathic pulmonary fibrosis (IPF) who failed previous therapy. The treatment period will be up to 1 year. The primary objective is evaluation of safety and efficacy. Secondary: The secondary objective is to evaluate quality of life (QoL) and pharmacokinetics (PK).", "condition": ["Pulmonary Fibrosis"], "intervention_type": ["Drug"], "intervention_name": ["Etanercept"], "criteria": "Inclusion Criteria: - Diagnosis of IPF based on American Thoracic Society (ATS) guidelines Exclusion Criteria: - Subjects with end-stage - Previous treatment with etanercept or other TNF antagonists (eg, a TNF monoclonal antibody or a soluble TNF-receptor) - Receipt of any investigational drug or biological agent within 4 weeks of screening visit", "gender": "All", "minimum_age": "40 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "keyword": "Fibroses, Pulmonary", "mesh_term": ["Fibrosis", "Pulmonary Fibrosis", "Idiopathic Pulmonary Fibrosis", "Idiopathic Interstitial Pneumonias", "Etanercept"], "id": "NCT00063869"}